NICE Approves Givinostat for DMD and EU Critical Medicines Act Progress

Episode 10 — 14 May 2026NICE approves givinostat (Duvyzat) for NHS use in England — the third treatment recommended for Duchenne muscular dystrophy, benefiting around 530 people. Evidence suggests it may delay loss of walking ability by around five years compared with established care. Marcus and Sara examine what this approval reveals about NICE's approach to rare disease evidence under uncertainty, and the HTA implications for the broader ATMPs pipeline.Plus: EU Critical Medicines Act progress, HTACG capacity building across member states, and ISPOR 2026 in Philadelphia this week.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast